Vendor Intelligence Report: Verified Peptides

Published 13 Jun 2026. 27-page investigative report on who is behind Verified Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 36 Finnrick lab tests, Verified Peptides has an overall pass rate of 50% (18 pass / 18 fail). The record is not a blanket rejection, but it is sharply product-specific. Semaglutide and Tirzepatide are the comparatively strong end of the tested catalog; CJC-1295 and BPC-157 are the weak standouts, and ratings contract under stricter grading.

The corporate record is a transparency problem, not a solved ownership map. Archived terms connect the storefront to a Florida LLC; Florida filings point through a New Mexico member; and the visible operating address resolves to a virtual mailbox. Annual reports show changing signatories, but the public trail does not identify a peptide-qualified principal, quality officer, warehouse, manufacturer, or ultimate beneficial owner.

Verified Peptides does use Janoshik Analytical COAs, which is a real positive. The problem is completeness: the report cross-checks vendor testing claims against Disclosed Labs and finds same-day failures with identical 76.4% purity results, plus a later LL-37 failure, that were not visible in the vendor's public lab archive during the June review. Safety-panel coverage also sits uneasily beside broad endotoxin and sterility language.

The reputation layer adds more friction. A 4.9/5 Trustpilot presentation is preserved in archive, while the current Trustpilot page says the profile was removed for guideline violations; community-review signals show astroturf indicators rather than clean validation. Supply-chain searches, meanwhile, produced dead ends rather than a named manufacturer.

Inside the full report:

  • Finnrick per-product pass/fail rates, methodology-divergence charts, and Appendix A lab-data table for all 8 tested products
  • Florida filings, archived Terms/Privacy captures, and annual-report signatory exhibits mapping the operating entity and ownership layer
  • Disclosed Labs failure cross-check, including the identical 76.4% purity entries and safety-panel coverage analysis
  • Janoshik COA review and buyer guidance for batch matching, report verification, endotoxin, and sterility documentation
  • Trustpilot archive/removal exhibits and Peptigrity review-quality analysis
  • Supply-chain dead-end review covering import-record searches, Cloudflare/Squarespace infrastructure, and sister-brand checks

Risk assessment

  • Ownership and accountability opacity — high: Veripeppy LLC uses a Miami virtual mailbox and is controlled in filings by New Mexico Life Through Science LLC; public records supplied do not identify beneficial owners.
  • Supply-chain traceability concern — medium: No ImportYeti or Customs records were found for Veripeppy LLC or Verified Peptides, while vendor materials imply undisclosed manufacturers and NDA limits.
  • Testing-transparency and safety-panel concern — high: Disclosed Labs lists unpublished Pinealon, TB-500 and unspecified Verified Peptide failures at 76.4% plus LL-37 at 94.08%; Safety Panel Coverage is 48/100.
  • Product-specific quality inconsistency — high: Finnrick testing is 36 tests split 18 pass / 18 fail; CJC-1295 (29.66%) and BPC-157 (41.47%) are weak, while tirzepatide and semaglutide are the 4/4 pass standouts.
  • Marketing trust-signal concern — high: A 4.9/5 Trustpilot badge was observed while Trustpilot now says the profile was removed for guideline violations; Peptigrity shows astroturfing indicators.
  • Brand-confusion and authenticity concern — medium: An unrelated 2026 Verified Peptide Supplier press-release lead surfaced, and the investigation did not find an authorized-channel, reseller, or anti-counterfeit guide.